Drugs / ALS-002200
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01590407 | Dec 2011 → Feb 2013 | chronic hepatitis C virus infection | Alios Biopharma Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALS-002200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01590407 ↗ |
| Route | Oral | “orally administered ALS-002200” NCT01590407 ↗ |